interview with Anastasiya Tatarnikova, Chairman at the Centre of Expert Help to Patients with Rare Diseases (House of Patients with Orphan Diseases)
Published on 2 November 2020 by Anna Andriyanova
Orphan drugs are a never-ending challenge for the healthcare system due to their high cost and the need for top-down action. Will the industry find ways to tackle rare diseases? Will the top-level breakthrough initiatives work?